The company submits an orphan drug application to FDA for its Cell-in-a-Box treatment for pancreatic cancer.
Nuvilex, a clinical-stage biotechnology company, announced that it has applied for Orphan Drug Designation in the United States for its Cell-in-a-Box treatment for pancreatic cancer. The US submission follows the application Nuvilex made to the European Medicines Agency in September 2014. Orphan Drug Designation in the US is given to drugs or treatments for rare, life-threatening diseases and provides special development and commercial assistance from FDA, including a seven-year period of marketing exclusivity.
According to the company, Nuvilex's pancreatic cancer treatment provides targeted chemotherapy by combining its the Cell-in-a-Box cellulose-based live cell encapsulation technology with low doses of the anticancer prodrug ifosfamide. Cells enclosed in pin-head-sized capsules during the Cell-in-a-Box encapsulation process convert ifosfamide into its cancer-killing form at or near the site of the tumor.
"Submission for Orphan Drug Designation in the US is the next logical step for the development of Nuvilex's pancreatic cancer treatment, and we look forward to hearing back from the FDA regarding our application," commented Kenneth L. Waggoner, Nuvilex's CEO and president, in a press release.
Source: Nuvilex
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.